Fosamax Osteonecrosis of the Jaw Settlement: New Jersey Injury Lawyer

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of General Health and Science Information

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This legacy context has empowered individuals to engage with complex health topics, from chronic disease management to pharmaceutical interventions. Within this broad framework, discussions of bone health and osteoporosis treatments have been routine, with patients and providers alike relying on established guidelines for safe and effective care. As this informational heritage evolves, a more specialized concern has emerged: the intersection of pharmaceutical exposure and rare but serious adverse outcomes. Specifically, the use of bisphosphonate medications such as Fosamax has been linked to a heightened risk of osteonecrosis of the jaw, a condition involving bone tissue death in the mandible or maxilla. This risk is particularly relevant in occupational settings where individuals may have prolonged or repeated exposure to such agents, whether through direct patient care, manufacturing, or environmental contact. The transition from general health awareness to occupational exposure concern requires careful attention to the specific circumstances under which risk may be elevated, without overstating mechanistic certainty. This pivot acknowledges that while the general public benefits from broad health education, certain professional roles demand a more targeted understanding of exposure pathways and their potential consequences.

Bridge: From General Awareness to Specific Risk

Building on the legacy of general health information, we now focus on the specific risk of osteonecrosis of the jaw (ONJ) associated with Fosamax (alendronate). Fosamax is a bisphosphonate medication prescribed to treat osteoporosis and other bone conditions. A known adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw. This condition involves the death of jawbone tissue, which can lead to pain, swelling, infection, and exposed bone in the mouth. The following sections synthesize evidence from FDA-approved labeling and peer-reviewed research to describe the clinical presentation, pharmacological context, mechanistic pathways, and risk considerations relevant to patients and legal settlements.

Clinical Presentation and Diagnosis of Osteonecrosis of the Jaw

Osteonecrosis of the jaw is characterized by the presence of exposed, non-healing bone in the maxillofacial region, often occurring after dental procedures such as tooth extraction or dental implant placement. According to FDA-approved labeling for Fosamax, ONJ "can occur spontaneously" but is "generally associated with tooth extraction and/or local infection with delayed healing" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition may present with symptoms such as pain, swelling, paresthesia, or drainage from the affected area. Diagnosis typically involves clinical examination and imaging, though the labeling notes that "clinical judgment of the treating physician and/or oral surgeon should guide the management plan" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Multiscale characterization of jawbone tissue has been used to better understand the bone-specific responses that contribute to ONJ, including in the context of postmenopausal osteoporosis and bisphosphonate-related complications (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Fosamax Pharmacology and Reported Adverse Effects

Fosamax (alendronate) works by inhibiting osteoclast-mediated bone resorption, which reduces bone turnover. This mechanism, while beneficial for increasing bone density in osteoporosis, can also suppress normal bone remodeling in the jaw. The FDA labeling for Fosamax reports that ONJ has been observed in patients taking bisphosphonates, including alendronate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The time to onset of ONJ symptoms can vary widely, from "one day to several months after starting the drug" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups, suggesting that ONJ is a rare event in the general population but may be more common in those with additional risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The labeling also notes that "most patients had relief of symptoms after stopping" the drug, though "a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Mechanistic Pathways Linking Fosamax to Osteonecrosis of the Jaw

The exact mechanism by which bisphosphonates like Fosamax contribute to ONJ is not fully understood, but several pathways have been proposed. Bisphosphonates accumulate in bone, particularly in areas of high turnover such as the jaw, and suppress osteoclast activity. This suppression can impair the normal healing response after dental trauma or infection, leading to bone necrosis. The FDA labeling identifies known risk factors that may increase susceptibility, including "invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures)" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Additionally, the risk of ONJ "may increase with duration of exposure to bisphosphonates" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Research using multiscale characterization of jawbone has provided insights into how bone structure and cellular responses may predispose the jaw to ONJ, particularly in the context of bisphosphonate therapy (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Risk Anchors: Adequacy of Warnings, Settlement Considerations, and Timeline

The adequacy of warnings regarding Fosamax and ONJ is a central issue in legal claims. The FDA-approved labeling includes a specific section on ONJ, detailing risk factors, clinical presentation, and management recommendations. However, patients and legal representatives may argue that these warnings were not sufficiently communicated to prescribers or patients prior to the development of ONJ. The labeling advises that "for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). It also states that "patients who develop osteonecrosis of the jaw while on bisphosphonate therapy should receive care by an oral surgeon" and that "extensive dental surgery to treat ONJ may exacerbate the condition" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Discontinuation of bisphosphonate therapy should be considered based on individual benefit/risk assessment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Settlement-related considerations for affected patients often involve evaluating the strength of the causal link between Fosamax use and ONJ, the severity of the injury, and the adequacy of the manufacturer's warnings. The timeline between exposure and documented harm is variable. The labeling notes that symptom onset can range from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, ONJ is considered a rare adverse event. One study found that the incidence of ONJ was "uncommon and rare respectively" compared to other fractures, and that interruption of bisphosphonate prescription for up to two years after three or five years of use was not associated with an increased risk of fragility fracture (https://pubmed.ncbi.nlm.nih.gov/42046648/). This suggests that while ONJ is a serious condition, it occurs infrequently, and the risk may be mitigated by careful dental management and periodic drug holidays.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it linked to osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate medication used to treat osteoporosis. It has been associated with osteonecrosis of the jaw (ONJ), a condition where jawbone tissue dies, often after dental procedures. The FDA labeling notes that ONJ can occur spontaneously or after tooth extraction (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the symptoms of osteonecrosis of the jaw?

Symptoms include pain, swelling, infection, exposed bone in the mouth, paresthesia, or drainage. Diagnosis involves clinical exam and imaging, and management should be guided by a physician or oral surgeon (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long after starting Fosamax can osteonecrosis of the jaw occur?

Onset can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while on Fosamax?

Risk factors include invasive dental procedures, cancer, chemotherapy, corticosteroids, poor oral hygiene, periodontal disease, anemia, and longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Can stopping Fosamax help with osteonecrosis of the jaw?

Most patients experience relief after stopping the drug, but some may have recurrence if rechallenged. Discontinuation should be based on individual risk-benefit assessment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.